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P R E V I E W S
In this issue of Cancer Cell, Rahman et
al. present data showing that high levels
of thymidylate synthase (TS), generated
by the transduction of immortalized
mouse cell lines with human TS cDNA or
by induction via a tetracyline-
responsive promoter, result
in transformation. By the cri-
teria of anchorage indepen-
dence and tumor formation in
nude mice, they show that a
high level of TS is capable of
transforming these cells to
malignancy. Thus, TS may be
considered a protooncogene
in that it is a normal protein
that functions as a positive
regulator of growth and is
converted to an oncogene by
overexpression.
Does a high level of TS
expression contribute to
tumor growth in patients?
Studies show that most
metastatic colorectal can-
cers have high levels of TS
mRNA and protein as com-
pared to primary colorectal
cancers and that primary col-
orectal cancers have higher
levels of TS as compared 
to normal colonic tissue.
Several studies also show
that patients with metastatic
colorectal cancer with tumors
that have high levels of TS
are less likely to respond to
treatment with 5-fluorouracil
than patients with lower lev-
els of this enzyme (reviewed
by Aschele et al., 2002; Bertino and
Banerjee, 2003; vanTriest and Peters,
1999). Only 20%–30% of patients have
what are considered low levels of this
enzyme, possibly related to deletion of a
portion of one of the alleles of chromo-
some 18, the location of the TS gene
(Bardot et al., 1991). Of interest, high TS
levels in the primary tumor have been
associated with a poor outcome, regard-
less of treatment (Edler et
al., 2002).
The high levels of TS in
some tumors have been
attributed to one of two
mechanisms: an increase in
gene copies of TS (only
5%–7%) or increased tran-
scriptional activation as a
result of the transcription fac-
tor E2F-1 (Degregori et al.,
1995). E2F-1 heterodimer-
izes with DP-1 and DP-2 and
activates the transcription of
genes encoding DNA syn-
thetic enzymes, including TS
(Banerjee et al., 1998).
Interestingly, E2F-1 has itself
been described as an onco-
gene or an oncogenic mes-
senger. Indeed, a recent
report indicates that most
metastatic colorectal tumors
overexpress E2F-1, associ-
ated with amplification of this
gene, raising the possibility
that TS is simply a player in
malignant transformation
attributed to E2F-1 (Iwamoto
et al., 2004).
A second question that
arises is whether or not the
oncogenic activity that is
attributed to TS is related to
its enzyme activity. TS is a
Thymidylate synthase as an oncogene?
A surprising finding in the report by Rahman et al. in this issue of Cancer Cell is that forced overexpression of human
thymidylate synthase transforms immortalized murine cells into a malignant phenotype. We discuss the possibility that
elevated levels of thymidylate synthase noted in some human malignancies may contribute to tumor progression and may
also reflect increased levels of its transcriptional activator E2F-1.
Figure 1. The thymidylate cycle
E2F-1 as the heterodimer E2F-1/DP-1 activates transcription of TS. The
other two enzymes of the thymidylate cycle are dihydrofolate reduc-
tase (DHFR) and serine hydroxymethyltransferase (SHMT). FH2,
dihydrofolate; FH4, tetrahydrofolate; CH2FH4, 5-10-methylene tetrahy-
drofolate.
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well-studied enzyme because of its key
role in DNA synthesis and, as such, is a
target for anticancer drug development.
5-fluorouracil and fluorodeoxyuridine,
clinically useful drugs, when converted to
5-fluorodeoxyuridylate is a potent com-
petitive inhibitor of dUMP, the substrate
for this enzyme. Competitive inhibitors of
the coenzyme for this reaction, 5-10-
methylene tetrahydrofolate, have also
been developed, and two of these, ralti-
texed and pemetrexed, have been
approved for use in patients with colorec-
tal cancer (in Europe and Canada) and
mesothelioma, respectively. TS is the
rate- limiting enzyme in the thymidylate
cycle; thus, the rate of thymidylate syn-
thesis is controlled by the level of TS and
the concentration of its substrate dUMP
and its coenzyme 5-10-methylene
tetrahydrofolate (see Figure 1). In this
regard, it should be noted that activity
measured in cell lysates, in which con-
centrations of dUMP and 5-10-methyl-
enetetrahydrofolate are much higher than
Km values, may not accurately reflect TS
activity in the cell, where these concen-
trations are usually less than or equal to
Km. Why is this important? The premise
of the authors is that it is the increase in
enzyme activity that drives cells toward
malignant transformation. They support
this premise by showing that the
overexpression of TS proteins that lack
enzymatic activity did not cause transfor-
mation in NIH-3T3 cells or tumor forma-
tion. While this is a plausible hypothesis,
an alternate explanation that should be
considered is that elevated levels of TS
act as a proliferative stimulus through a
nonenzymatic mechanism that is also
abrogated by the mutations that affect
activity. Indeed, TS has been shown to be
a promiscuous protein that binds to TS
mRNA as well as to several other
mRNAs, including those for c-Myc and
p53 (Liu et al., 2002). Binding to its cog-
nate mRNA has been shown to inhibit
translation. Treatment of cells with 5-fluo-
rouracil results in an increase of TS
protein by relieving this translational inhi-
bition (Liu et al., 2002). A recent study by
Berger and associates suggests that this
increase may also be a result of
decreased degradation of this protein
when bound to the inhibitor (Forsthoefel
et al., 2004).
In summary, an alternative scenario
to the one proposed by Rahman et al.
(2004) is that TS is upregulated due to
the overexpression of the protoonco-
gene E2F-1 and effects an oncogenic
phenotype through a nonenzymatic
coopting of mRNAs involved in the
expression of growth regulatory genes.
In this case, TS itself is not acting as an
oncogene or even as an enzyme.
However, regardless of which strategy
for transformation is confirmed, a central
role for TS in tumorigenicity seems
apparent, and the report in this issue
should stimulate additional enquiry into
the functions of TS and encourage con-
tinued development of methods to inter-
fere with these function(s).
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